Intelligent Bio Solutions Inc. (INBS)
NASDAQ:INBS
Want to see INBS full AI Analyst Report?
INBS Stock Chart & Stats
$1.03
-$0.03(-2.02%)
At close: 4:00 PM EST
$1.03
-$0.03(-2.02%)
Day’s Range― - ―
52-Week Range$2.27 - $24.90
Previous CloseN/A
Volume32.28K
Average Volume (3M)165.11K
Market Cap
$6.03M
Enterprise Value-$3.35M
Total Cash (Recent Filing)$6.86M
Total Debt (Recent Filing)$1.85M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.52
Shares Outstanding2,391,846
10 Day Avg. Volume182,067
30 Day Avg. Volume165,108
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.03
Price to Sales (P/S)2.97
P/FCF Ratio-0.92
Enterprise Value/Market Cap-0.56
Enterprise Value/Revenue-0.86
Enterprise Value/Gross Profit-2.67
Enterprise Value/Ebitda0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing Scale & Cost CutsA strategic manufacturing partnership delivering fourfold capacity and targeted >40% production cost savings is a durable structural improvement. It supports faster order fulfillment, inventory build for U.S. expansion, and meaningful long-term margin expansion if demand scales as planned.
Vertical Integration And R&D ThroughputDoubling in-house strip production strengthens supply control, reduces dependence on external vendors, and accelerates product iteration. That durable internal capability lowers unit costs, shortens development cycles, and enables tailored test panels across markets and regulations.
Recurring Consumables + Installed Base ModelA hardware-plus-consumables model creates repeatable, usage-driven revenue and higher lifetime customer value. As installed readers grow, recurring cartridge sales and services can sustainably amplify revenue and margins independent of one-time device sales.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow at roughly -$11M TTM creates an ongoing funding requirement. Unless operating margins improve or revenue scales materially, the firm will need external capital, constraining strategic optionality and raising execution risk over months.
Deep Negative Profitability & Margin ErosionExtremely negative net margins and a material decline in gross margin indicate the cost structure is not yet aligned with revenue. This persistent unprofitability lengthens the path to sustainable free cash flow and pressures returns even as top-line improves modestly.
Reliance On Equity Financing & Dilution RiskFrequent equity grants, warrant exercises and an active ATM program signal ongoing dependence on equity to fund operations. Over time this dilutes existing shareholders, can depress per-share economics, and indicates limited near-term internal cash generation.
Intelligent Bio Solutions News
INBS FAQ
What was Intelligent Bio Solutions Inc.’s price range in the past 12 months?
Intelligent Bio Solutions Inc. lowest stock price was $2.27 and its highest was $24.90 in the past 12 months.
What is Intelligent Bio Solutions Inc.’s market cap?
Intelligent Bio Solutions Inc.’s market cap is $6.03M.
When is Intelligent Bio Solutions Inc.’s upcoming earnings report date?
Intelligent Bio Solutions Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 158 days.
How were Intelligent Bio Solutions Inc.’s earnings last quarter?
Intelligent Bio Solutions Inc. released its earnings results on May 13, 2026. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.8.
Is Intelligent Bio Solutions Inc. overvalued?
According to Wall Street analysts Intelligent Bio Solutions Inc.’s price is currently Overvalued.
Does Intelligent Bio Solutions Inc. pay dividends?
Intelligent Bio Solutions Inc. does not currently pay dividends.
What is Intelligent Bio Solutions Inc.’s EPS estimate?
Intelligent Bio Solutions Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intelligent Bio Solutions Inc. have?
Intelligent Bio Solutions Inc. has 2,391,846 shares outstanding.
What happened to Intelligent Bio Solutions Inc.’s price movement after its last earnings report?
Intelligent Bio Solutions Inc. reported an EPS of -$1.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 25.472%.
Which hedge fund is a major shareholder of Intelligent Bio Solutions Inc.?
Currently, no hedge funds are holding shares in INBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Technical Analysis
Ownership Overview
3.78% Insiders
0.63% Mutual Funds
7.03% Other Institutional Investors
88.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---